Ftse Mib
34.660,38
-0,50%
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
NASDAQ
17.133,13
-0,23%
Bitcoin
69.315,33
-2,05%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Veracyte Inc (VCYT) Veracyte Inc (VCYT) Notizie

VCYT

Veracyte (VCYT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VCYT
DataOraFonteTitoloSimboloCompagnia
04/06/202422:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VCYTVeracyte Inc
03/06/202422:05Business WireVeracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid TumorsNASDAQ:VCYTVeracyte Inc
28/05/202422:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VCYTVeracyte Inc
22/05/202422:05Business WireVeracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and CancerNASDAQ:VCYTVeracyte Inc
15/05/202423:04Business WireVeracyte to Participate in Upcoming Investor ConferencesNASDAQ:VCYTVeracyte Inc
08/05/202423:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VCYTVeracyte Inc
07/05/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VCYTVeracyte Inc
07/05/202422:05Business WireVeracyte Announces First Quarter 2024 Financial ResultsNASDAQ:VCYTVeracyte Inc
06/05/202422:05Business Wire14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease UnderstandingNASDAQ:VCYTVeracyte Inc
22/04/202423:00Business WireVeracyte to Release First Quarter 2024 Financial Results on May 7, 2024NASDAQ:VCYTVeracyte Inc
22/04/202414:30Business WireNew Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceNASDAQ:VCYTVeracyte Inc
16/04/202414:30Business WireVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024NASDAQ:VCYTVeracyte Inc
29/02/202423:22Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:VCYTVeracyte Inc
29/02/202423:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VCYTVeracyte Inc
29/02/202422:40Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VCYTVeracyte Inc
29/02/202414:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VCYTVeracyte Inc
27/02/202423:55Business WireVeracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN GuidelinesNASDAQ:VCYTVeracyte Inc
22/02/202422:05Business WireVeracyte Announces Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:VCYTVeracyte Inc
21/02/202423:00Business WireVeracyte to Participate in the Raymond James 45th Annual Institutional Investors ConferenceNASDAQ:VCYTVeracyte Inc
08/02/202414:00Business WireVeracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024NASDAQ:VCYTVeracyte Inc
06/02/202414:15Business WireVeracyte Completes Acquisition of C2i GenomicsNASDAQ:VCYTVeracyte Inc
29/01/202422:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VCYTVeracyte Inc
08/01/202414:00Business WireVeracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics PlatformNASDAQ:VCYTVeracyte Inc
12/12/202322:30Business WireVeracyte to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VCYTVeracyte Inc
01/12/202322:05Business WireReal-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to ProgressNASDAQ:VCYTVeracyte Inc
29/11/202314:30Business WireClinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung NodulesNASDAQ:VCYTVeracyte Inc
22/11/202314:30Business WireVeracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023NASDAQ:VCYTVeracyte Inc
07/11/202322:05Business WireVeracyte Announces Third Quarter 2023 Financial ResultsNASDAQ:VCYTVeracyte Inc
07/11/202322:00Business WireVeracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients GloballyNASDAQ:VCYTVeracyte Inc
02/11/202313:15Business WireVeracyte to Participate in the Stephens Annual Investment ConferenceNASDAQ:VCYTVeracyte Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VCYT

La tua Cronologia

LSE
91NP
Sg Issuer 26
COIN
VEUR
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network